Drug intelligence / Profile preview

CHALL-2020

Development stage: Unknown
Lead developer: Changhai Hospital
Modality: Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules

Overview

CHALL-2020 is a multi-agent treatment protocol developed by Changhai Hospital of the Naval Medical University for adult patients with acute lymphoblastic leukemia (ALL). It represents a risk-stratified, intensified therapeutic strategy that combines a backbone of traditional chemotherapy (vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone) with targeted therapies tailored to the patient's molecular profile. Specifically, it incorporates the BCR-ABL inhibitor dasatinib for Philadelphia chromosome-positive (Ph+) ALL and the anti-CD20 monoclonal antibody rituximab for CD20-positive ALL. The protocol includes induction, consolidation, and maintenance phases, along with central nervous system (CNS) prophylaxis, aiming to optimize complete remission rates and minimize minimal residual disease (MRD) in the adult ALL population.

Other names: CHALL-2020 protocolCHALL2020 protocolCHALL 2020 protocolCHALL-2020 regimenCHALL2020 regimenCHALL 2020 regimen

Targets

DNACD20 (B-lymphocyte antigen CD20)DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)Nucleotide synth (Nucleotide synthesis enzymes)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on CHALL-2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHALL-2020.

Explore the full profile